Bee Venom as A Potential Therapeutic Agent Against Human Chronic Myeloid Leukemia Cells


Creative Commons License

Halıcı H., Ün H., Çelik S., Karaköy Z., Bayraktutan Z., Özlü C., ...Daha Fazla

6th Eurasia Biochemical Approaches & Technologies (EBAT) 2024 , Tokat, Türkiye, 24 - 27 Ekim 2024, ss.31

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Tokat
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.31
  • Erzincan Binali Yıldırım Üniversitesi Adresli: Evet

Özet

Honey, a bee and bee product, as old as human history; is seen that it was used as a healing source in many inscriptions and ruins in every period of its history. Propolis, pollen, royal jelly and beeswax, which are the honey and products they produce, have been used by people for thousands of years to treat many diseases 1.The antiproliferative effects of bee venom on K-562 chronic myeloid leukemia cells were researched in this study. The cells proliferated in the incubator were firstly counted with a cell counter. Afterward, these cells were performed culture to 96-well cell plates for MTT testing, in a way to 1x10cells / 100μl medium to per well and 1x10cells / 500μl medium to per well of 24-cell plates for the drug-cell interaction test. Later, drugs were given to the wells in determining doses. The effects of bee venom on cell viability at 24th, 48th and 72nd hours and on drug-cell interaction were researched. According to MTT results, it was found that bee venom decreased K-562 cell viability in all hours depending on the dose. It was found that cell numbers decreased at 48th and 72nd hours after drug applications. Nonetheless, it was found that the cell numbers increased during 72 hours in the control group that was not administered a medication. When the drug interactions were analyzed, it was found that the cell surfaces, which were plain and clear before the medicine was administered, gradually distorted and began to shrink after that time the medicine was administered. As a result, it has been found that bee venom has a strong antiproliferative effect in K-562 chronic myeloid leukemia cell lines with increasing doses.